The synthetic cathelicidin HHC-10 inhibits mycobacterium bovis BCG in vitro and in C57BL/6 mice

Microbial Drug Resistance

Volumn 19, Issue 2, 2013, Pages 124-129

  Llamas González, Yessica Yadira ^a   Pedroza Roldán, César ^a   Cortés Serna, Marissa Beatriz ^a   Márquez Aguirre, Ana Laura ^a   Gálvez Gastélum, Francisco Javier ^b   Flores Valdez, Mario Alberto ^a  

^a CENTRO DE INVESTIGACIÓN Y ASISTENCIA EN TECNOLOGÍA Y DISEÑO DEL ESTADO DE JALISCO   (Mexico)

^b UNIVERSITY OF GUADALAJARA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CATHELICIDIN HHC 10; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL LOAD; COLONY FORMING UNIT; CONTROLLED STUDY; FEMALE; GRANULOMA; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LUNG PARENCHYMA; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUBERCULOSIS;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; ANTITUBERCULAR AGENTS; COLONY COUNT, MICROBIAL; FEMALE; INTERFERON-GAMMA; INTERLEUKIN-10; LUNG; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM BOVIS; SPLEEN; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; MUS; MYCOBACTERIUM BOVIS; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS COMPLEX;

EID: 84875624049     PISSN: 10766294     EISSN: 19318448     Source Type: Journal    
DOI: 10.1089/mdr.2012.0149     Document Type: Article

References (21)

1. Bals, R., D.J. Weiner, A.D. Moscioni, R.L. Meegalla, and J.M. Wilson. 1999. Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infect. Immun. 67:6084-6089.
2. Barlow, P.G., P. Svoboda, A. Mackellar, A.A. Nash, I.A. York, J. Pohl, D.J. Davidson, and R.O. Donis. 2011. Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS One 6:e25333.
3. Bean, A.G., D.R. Roach, H. Briscoe, M.P. France, H. Korner, J.D. Sedgwick, and W.J. Britton. 1999. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J. Immunol. 162:3504-3511.
4. Bommarius, B., H. Jenssen, M. Elliott, J. Kindrachuk, M. Pasupuleti, H. Gieren, K.E. Jaeger, R.E. Hancock, and D. Kalman. 2010. Cost-effective expression and purification of antimicrobial and host defense peptides in Escherichia coli. Peptides 31:1957-1965.
5. Brogden, K.A. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3: 238-250.
6. Cherkasov, A., K. Hilpert, H. Jenssen, C.D. Fjell, M. Waldbrook, S.C. Mullaly, R. Volkmer, and R.E. Hancock. 2009. Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibioticresistant superbugs. ACS Chem. Biol. 4:65-74.
7. Flores-Valdez, M.A., and S. Chopra. 2010. Global reemergence of tuberculosis: are host defense peptides an option to ameliorate disease burden? Microb. Drug Resist. 16:1-7.
8. Flynn, J.L., and J. Chan. 2001. Immunology of tuberculosis. Annu. Rev. Immunol. 19:93-129.
9. Flynn, J.L., M.M. Goldstein, J. Chan, K.J. Triebold, K. Pfeffer, C.J. Lowenstein, R. Schreiber, T.W. Mak, and B.R. Bloom. 1995. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2:561-572.
10. Fulton, S.A., T.D. Martin, R.W. Redline, and W. Henry Boom. 2000. Pulmonary immune responses during primary Mycobacterium bovis-Calmette-Guerin bacillus infection in C57Bl/6 mice. Am. J. Respir. Cell Mol. Biol. 22:333-343.
11. Gandhi, N.R. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575-1580.
12. Gong, J.H., M. Zhang, R.L. Modlin, P.S. Linsley, D. Iyer, Y. Lin, and P.F. Barnes. 1996. Interleukin-10 downregulates Mycobacterium tuberculosis-induced Th1 responses and CTLA-4 expression. Infect. Immun. 64:913-918.
13. Jenssen, H., and. R.E. Hancock. 2010. Therapeutic potential of HDPs as immunomodulatory agents. Methods Mol Biol 618:329-347.
14. Kandler, K. 2006. The anti-microbial peptide LL-37 inhibits the activation of dendritic cells by TLR ligands. Int. Immunol. 18:1729-1736.
15. Lai, Y., and R.L. Gallo. 2009. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 30:131-141.
16. Maloney, E., D. Stankowska, J. Zhang, M. Fol, Q.J. Cheng, S. Lun, W.R. Bishai, M. Rajagopalan, D. Chatterjee, and M.V. Madiraju. 2009. The two-domain LysX protein of Mycobacterium tuberculosis is required for production of lysinylated phosphatidylglycerol and resistance to cationic antimicrobial peptides. PLoS Pathog 5:e1000534.
17. Martineau, A.R., S.M. Newton, K.A. Wilkinson, B. Kampmann, B.M. Hall, N. Nawroly, G.E. Packe, R.N. Davidson, C.J. Griffiths, and R.J. Wilkinson. 2007. Neutrophil- mediated innate immune resistance to mycobacteria. J. Clin. Invest. 117:1988-1994.
18. Miyakawa, Y., P. Ratnakar, A.G. Rao, M.L. Costello, O. Mathieu-Costello, R.I. Lehrer, and A. Catanzaro. 1996. In vitro activity of the antimicrobial peptides human and rabbit defensins and porcine leukocyte protegrin against Mycobacterium tuberculosis. Infect. Immun. 64: 926-932.
19. North, R.J. 1998. Mice incapable of making IL-4 or IL-10 display normal resistance to infection with Mycobacterium tuberculosis. Clin. Exp. Immunol. 113:55-58.
20. Raviglione, M.C. 2007. The new Stop TB strategy and the global plan to stop TB, 2006-2015. Bull. World Health Organ. 85:327.
21. Sonawane, A. 2011. Cathelicidin is involved in the intracellular killing of mycobacteria in macrophages. Cell. Microbiol. 13:1601-1617.